Sarah Noonberg Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sarah Noonberg PTGX stock SEC Form 4 insiders trading

Sarah has made over 1 trades of the Protagonist Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 8,400 units of PTGX stock worth 212,520$ on 10 February 2021.

The largest trade he's ever made was selling 8,400 units of Protagonist Therapeutics Inc stock on 10 February 2021 worth over 212,520$. On average, Sarah trades about 494 units every 0 days since 2017.

You can see the complete history of Sarah Noonberg stock trades at the bottom of the page.

Sarah Noonberg biography

Dr. Sarah B. Noonberg M.D., Ph.D. serves as Independent Director of the Company. She has served as a member of the Board since December 2017. Since May 2019, Dr. Noonberg has provided Chief Medical Officer consultant services to multiple private biotechnology companies. She previously served as Chief Medical Officer of Nohla Therapeutics, developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, from May 2018 to May 2019. Prior to joining Nohla Therapeutics, she served as the Chief Medical Officer of Prothena Corporation plc, a biotechnology company, from May 2017 to March 2018. Prior to joining Prothena, Dr. Noonberg served from August 2015 to March 2017 as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc., a biotechnology company, where she was responsible for development strategy and execution across a diverse clinical portfolio. From 2007 to August 2015, she held several positions at Medivation, Inc., a biopharmaceutical company, where, as Senior Vice President of Early Development and Vice President of Clinical Development, she led programs across all phases of development, including enzalutamide (XTANDI) for the treatment of chemotherapy-naïve metastatic prostate cancer. Dr. Noonberg also held several clinical positions between 2004 and 2007 at Chiron Corporation, where she led the clinical development of compounds in infectious disease and pulmonary indications. She has served on the board of directors of Neoleukin Therapeutics, a public biopharmaceutical company, since August 2019. Dr. Noonberg earned her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley, and her B.S. at Dartmouth College. She is a board-certified internist and completed her residency at Johns Hopkins Hospital. From 2002 to 2018, she was a part-time hospitalist, working as an attending physician treating a broad range of inpatient and critical care patients.

What is the salary of Sarah Noonberg?

As the Independent Director of Protagonist Therapeutics Inc, the total compensation of Sarah Noonberg at Protagonist Therapeutics Inc is 126,341$. There are 9 executives at Protagonist Therapeutics Inc getting paid more, with Dinesh Patel having the highest compensation of 1,948,340$.

How old is Sarah Noonberg?

Sarah Noonberg is 52, he's been the Independent Director of Protagonist Therapeutics Inc since 2017. There are 18 older and 2 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..

What's Sarah Noonberg's mailing address?

Sarah's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.

Insiders trading at Protagonist Therapeutics Inc

Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over 11,629,969$ worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth 35,519,073$ . The most active insiders traders include Capital Partners Gp, L.L.C....、& Johnson Johnson & Johnson...、X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of 2,387,307$. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth 103,040$.

What does Protagonist Therapeutics Inc do?

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

Complete history of Sarah Noonberg stock trades at Marinus Pharmaceuticals Inc、Protagonist Therapeutics Inc、Prothena plc、Neoleukin Therapeutics

Protagonist Therapeutics Inc executives and stock owners

Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dinesh Patel,
  President, Chief Executive Officer, Director
• Suneel Gupta,
  Chief Development Officer
• David Liu,
  Chief Scientific Officer, Head of Research & Development
• Dr. Dinesh V. Patel Ph.D.,
  CEO, Pres, Interim PAO, Sec. & Director
• Dr. David Y. Liu,
  Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel.
• Dr. Suneel K. Gupta Ph.D.,
  Chief Devel. Officer
• Harold Selick,
  Independent Chairman of the Board
• William Waddill,
  Independent Director
• Bryan Giraudo,
  Independent Director
• Sarah Noonberg,
  Independent Director
• Lewis Williams,
  Independent Director
• Sarah O'Dowd,
  Independent Director
• Brian Korb,
  IR Contact Officer
• Samuel Saks,
  Chief Medical Officer
• Donald Kalkofen,
  Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
• Asif Ali,
  Exec. VP & Chief Financial Officer
• Dr. Scott Eric Plevy M.D.,
  Exec. VP and Therapeutic Head of Gastroenterology
• Dr. Ashok Bhandari Ph.D.,
  Sr. VP of Discovery Chemistry & Process Research
• Mohammad Masjedizadeh,
  Exec. VP & CTO
• Donald A. Kalkofen,
  Chief Financial Officer
• Dr. Larry Mattheakis,
  Sr. VP of Discovery Biology & Translational Research
• Dr. Ashok Bhandari,
  Sr. VP of Discovery Chemistry & Process Research
• Carena Spivey,
  Exec. Director of HR
• Matthew M. Gosling,
  Exec. VP & Gen. Counsel
• Dr. Mark Smythe,
  Founder & VP Technology
• Dr. Richard S. Shames,
  Clinical Advisor
• Arturo Md Molina,
  Chief Medical Officer
• Armen Shanafelt,
  Director
• Chaitan Phd Khosla,
  Director
• Julie Papanek,
  Director
• Richard S. Shames,
  Chief Medical Officer
• Thomas P. O'neil,
  Chief Financial Officer
• William A Hodder,
  Sr. VP - Corporate Development
• & Johnson Johnson & Johnson...,
  
• X L.P.Canaan Partners X Llc...,
  
• Management Group, Llc Lilly...,
  
• Asif Ali,
  Chief Financial Officer
• Capital Partners Gp, L.L.C....,
  
• Daniel N Jr Swisher,
  Director